Fig. 12.
Comparisons between predicted and observed IC50 values for BRAF mutant and wild-type cell lines to three MEK1/2-inhibitors. (a) Consistence between the predicted response values by CDCN model I and the observed response values. (b) Consistence between the predicted response values by CDCN model II and the observed response values